Oral Proteins and Peptides Market Report 2026

The oral proteins and peptides market size has grown exponentially in recent years. It will grow from $1.56 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 22.5%. The growth in the historic period can be attributed to limited oral bioavailability of proteins and peptides, reliance on injectable formulations, growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, regulatory approvals for early oral peptide drugs.

The oral proteins and peptides market size is expected to see exponential growth in the next few years. It will grow to $4.26 billion in 2030 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to development of novel delivery technologies for oral proteins, expansion of chronic disease management programs, rising adoption of personalized and combination therapies, increasing healthcare expenditure on metabolic and hormonal disorders, integration of digital adherence and monitoring tools. Major trends in the forecast period include rising adoption of oral insulin and other therapeutic peptides, growth in personalized medicine and targeted oral protein therapies, increasing focus on gastrointestinal disorder treatments, expansion of oral protein formulations for diabetes and metabolic disorders, advancement in long-acting and combination oral protein products.

The expanding biopharmaceutical industry is anticipated to drive the growth of the oral proteins and peptides market in the coming years. The biopharmaceutical industry is a segment of the broader pharmaceutical sector that concentrates on the development, production, and commercialization of drugs derived from biological sources. The expansion of this industry is supported by advances in biotechnology, rising demand for personalized medicine, the increasing prevalence of chronic diseases, and higher investments in research and development. In biopharmaceutical applications, oral proteins and peptides provide the potential for non-invasive therapeutic delivery, improving patient compliance and minimizing the need for injectable treatments. They also enable targeted treatment of specific diseases while offering improved stability and absorption within the digestive system. For example, in October 2025, according to the Bioscience and Health Technology Sector, a UK-based government statistics source, during 2023/2024 there were 6,170 businesses operating in the UK life sciences industry across 7,320 companies. These organizations employed 359,600 people and generated £146.9 ($169.69) billion in turnover. As a result, the expansion of the biopharmaceutical industry is contributing to the growth of the oral proteins and peptides market.

Major companies operating in the oral proteins and peptides market are concentrating on the development of advanced formulation technologies to improve peptide stability, permeability, and bioavailability in oral dosage forms. These innovations are designed to address long-standing challenges such as enzymatic degradation and limited absorption in the gastrointestinal tract. For instance, in August 2025, BioMed X, a Germany-based biomedical research institute, entered into a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the development of next-generation oral peptide delivery technologies. This partnership focuses on exploring new molecular approaches and delivery mechanisms to enable safe, effective, and patient-friendly oral peptide therapies. By combining BioMed X’s early-stage research strengths with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance innovative oral drug delivery solutions and broaden the therapeutic applications of peptide medicines across metabolic and chronic conditions.

In April 2023, Chiesi Farmaceutici S.p.a., an Italy-based pharmaceutical company, acquired Amryt Pharma Plc for an undisclosed amount. This acquisition allows Chiesi to leverage Amryt’s unique product portfolio and promising development pipeline, strengthening its commitment to rare diseases and enhancing its biopharmaceutical capabilities. Amryt Pharma Plc is a UK-based company specializing in oral proteins and peptides.

Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.

North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral proteins and peptides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oral proteins and peptides market by increasing costs for imported biologics, excipients, and specialized delivery technologies. Segments like oral insulin formulations and long-acting peptide therapies are most affected, particularly in North America, Europe, and Asia-Pacific regions that depend on imports. This has led to higher production costs and potential delays in product availability. On the positive side, tariffs have encouraged domestic production, innovation in oral delivery systems, and diversification of local manufacturing capabilities.

The oral proteins and peptides market research report is one of a series of new reports that provides oral proteins and peptides market statistics, including oral proteins and peptides industry global market size, regional shares, competitors with a oral proteins and peptides market share, detailed oral proteins and peptides market segments, market trends and opportunities, and any further data you may need to thrive in the oral proteins and peptides industry. This oral proteins and peptides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral proteins and peptides refer to therapeutic proteins and peptide-based drugs that are administered by mouth, commonly in the form of tablets, capsules, or other ingestible preparations. These biologically active compounds are developed to manage a range of medical conditions by utilizing their targeted actions within the body.

The primary drug types of oral proteins and peptides include linaclotide, calcitonin, insulin, plecanatide, and octreotide. Their biological targets include guanylate cyclase-C (GC-C), the insulin receptor, oxalate, and others, while the mechanisms of action involve receptor stimulation, substrate degradation, and additional pathways. These therapies are applied across various indications such as gastrointestinal disorders, bone diseases, neurological disorders, diabetes, metabolic disorders, hormonal disorders, and cancer.

The oral proteins and peptides market consists of sales of protein supplements, peptide-based drugs, and therapeutic formulations designed for oral administration. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.